Migration Letters

Volume: 19, No: S2 (2022), pp. 1072-1081

ISSN: 1741-8984 (Print) ISSN: 1741-8992 (Online)

www.migrationletters.com

Overview Of X-Ray Crystallography In Drug Discovery And Development: A Review

Adnan Eshaq Alshennawi[1], Naif Abdulaziz A Alhamdan[2], Joud Saud Diab Alshamri[3], Fayez Shureed Almotiri[4], Ahdab Essam Hamad[5], Shahad Mohammed Batis[5], Manal Meshal F Alsharif[5], Haneen Adel Gusti[5], Mashael Abdullah Alghamdi[6], Basmah Saleh Almoualad[6], Fouad Hamdan Mohammed Alsahafi[7], Shagran Mohammed D Aldajani[8], Mohammed Jaber Hossain Azyabi[9], Bandar Mohammed A Bindawyan[10], Omar Mazyad Almotairi[11]

Abstract

X-ray crystallography is crucial in drug discovery and development by giving detailed structural data about target proteins and their interactions with[1] potential drug candidates. This review aims to provide an overview of the application of X-ray crystallography in the pharmaceutical industry, focusing on its role in understanding protein-ligand interactions, guiding rational drug design, and aiding in structure-based drug optimization. The study utilized secondary data from a variety of sources, including published research articles, review papers, and databases, to comprehensively review the current state of X-ray crystallography in drug discovery. Key topics covered include the basic principles of X-ray crystallography, the process of protein crystallization, data collection, and structure determination, as well as the challenges and limitations associated with this technique. By highlighting the successes and limitations of X-ray crystallography in drug discovery, this review aims to provide insights that can help researchers optimize the use of this powerful tool in the development of novel therapeutics. Ultimately, a better understanding of the role of X-ray crystallography in drug discovery and development can lead to the design of more effective and specific drug molecules with improved safety profiles.

Keywords: *X-ray crystallography, Drug optimization, Protein crystallization, Novel therapeutics, Drug molecules.*

1. Introduction

Because it offers comprehensive insights into the atomic-level structure of biological molecules, X-ray crystallography is a potent method that has transformed the process of finding

[1] Ray Technician, Dawadmi General Hospital, Saudi Arabia.
[2]radiological Technology, Thadiq General Hospital, Saudi Arabia.
[3]radiological Technology, Buraydah Central Hospital, Saudi Arabia.
[4] Ray Technician, Artawiya Hospital, Saudi Arabia.
[5]radiology Technician, King Fahad General Hospital, Saudi Arabia.
[6]radiographer, King Fahad General Hospital, Saudi Arabia.
[7]radiology Technician Altalaa Phc, Saudi Arabia.
[8]x-Ray Technician, General Directorate Of Health Affairs In Riyadh - Compliance Department, Saudi Arabia.
[9]technician-Radiological Technology, Health Affairs In Jazan Region. Southern Sector, Saudi Arabia.
[10]radiographer Technician, King Faisal Medical Complex In Taif, Saudi Arabia.
[11]ray Technician, Artawiya Hospital, Saudi Arabia.

and developing new drugs (Cooper, 2011). The purpose of this paper is to provide a general overview of the benefits, drawbacks, and uses of X-ray crystallography in the drug development process.

The first section of this review will cover the basic principles of X-ray crystallography, including the process of crystallization of biological molecules, diffraction of X-rays by crystals, and data collection and analysis (Erlanson, 2012). This will provide a foundation for understanding the subsequent sections that focus on the applications of X-ray crystallography in drug discovery.

The three-dimensional structures of pharmacological targets, including enzymes, receptors, and protein-protein complexes, have often been ascertained by the technique of X-ray crystallography (Hennig, 2011). With the use of this structural data, small molecule inhibitors or modulators that precisely target the target protein's active site may be created, opening the door to the creation of brand-new treatments (Mazzorana, 2020). Furthermore, X-ray crystallography may be used to improve the binding characteristics of current medications, clarify their methods of action, and address problems like drug resistance.

The capacity to offer high-resolution structural information, which enables researchers to see the interactions between medications and their targets in atomic detail, is one of the main benefits of X-ray crystallography in drug development (Spiliopoulou, 2020). Because it allows for the development of drug candidates for better potency, selectivity, and pharmacokinetic features, this information is crucial for rational drug design.

Moreover, the structure-activity interactions of medicinal compounds may be studied using X-ray crystallography, which can help in the creation of novel analogs with enhanced biological activity (Zhu, 2020). In the early phases of drug development, structural insights may assist in picking lead compounds for further optimization, which is where this knowledge can be very helpful.

Despite its many advantages, X-ray crystallography also presents several challenges in drug discovery. These include the need for high-quality protein crystals, the requirement for specialized equipment and expertise, and the potential limitations associated with certain types of proteins (Sinha, 2018). Overcoming these challenges requires a multidisciplinary approach, combining expertise in protein biochemistry, structural biology, and computational modeling.

In summary, X-ray crystallography plays a crucial role in drug discovery and improvement by giving detailed structural information that can guide the design and optimization of drug candidates. By understanding the principles, applications, advantages, and challenges of X-ray crystallography, researchers can harness the power of this technique to accelerate the development of novel therapeutics for a wide range of illnesses. This review aims to highlight the importance of X-ray crystallography in drug discovery and provide insights into its potential applications and limitations in the field.

2. Literature Review

Numerous earlier investigations have emphasized the significance of X-ray crystallography in the process of finding and developing new drugs. For instance, Mishin et al. (2019) showed how the structure of the integrin αvβ3 receptor linked to a small molecule inhibitor could be determined using X-ray crystallography. This structural knowledge played a key role in the creation of a novel class of more potent and selective integrin inhibitors.

García-Nafría et al. (2020) conducted research that emphasized the significance of X-ray crystallography in the identification of new antibiotics that target bacterial ribosomes. Through the analysis of the ribosome's crystal structure in conjunction with a small-molecule antibiotic, the researchers were able to clarify the drug's mechanism of action and enhance its affinity for binding.

According to the findings of research that was conducted by Davies et al. (2012), X-ray crystallography was able to help the structure-based design of a powerful inhibitor of an oncogenic protein. This was accomplished by exposing the essential binding interactions that occurred between the inhibitor and the target protein.

Another study by Brader et al. (2017) showcased the use of X-ray crystallography in elucidating the binding mode of a novel antibiotic against a bacterial enzyme. The researchers were able to optimize the compound's structure to improve its potency and selectivity by leveraging the structural information obtained from X-ray crystallography.

Zheng et al. (2015) provided useful information for rational drug design by demonstrating how X-ray crystallography was used to determine the structural basis of interaction between a drug candidate and its target protein.

In another study by Shi et al. (2014), X-ray crystallography was utilized to investigate the binding mode of a potential drug molecule to its target enzyme, revealing critical structural features that could be optimized to enhance drug potency and selectivity.

A study by Rodríguez et al. (2020) demonstrated how X-ray crystallography can be used to visualize the binding interactions between a drug and its protein target, providing important information for drug optimization and lead compound selection.

Similarly, a study by Mastrangelo et al. (2013) showcased the use of X-ray crystallography in drug discovery by determining the structure of a novel drug candidate bound to its target protein. This structural information allowed researchers to understand the mode of action of the drug and make improvements to its potency and selectivity.

Overall, these studies underscore the critical role of X-ray crystallography in drug discovery and development, highlighting its potential to accelerate the design of novel therapeutics with improved efficacy and safety profiles. By providing detailed insights into the structure-activity relationships of drug candidates, X-ray crystallography enables researchers to rationally design molecules with enhanced pharmacological properties, ultimately advancing the development of new treatments for a wide range of diseases.

3. Methodology

The construction of this review article was accomplished by undertaking an exhaustive search of the available literature on the use of X-ray crystallography in the process of drug discovery and growth. The purpose of this search was to locate relevant publications that were published in journals that were subjected to peer review. The search was conducted utilizing a variety of databases, such as PubMed, Scopus, Web of Science, and Google Scholar.

The search terms used included "X-ray crystallography," "drug discovery," "drug development," "protein-ligand complex," and other related keywords. Articles published in the last decade were given priority, but older articles were also considered if they were deemed relevant to the topic.

Following this, the publications that were chosen for review were examined, and material regarding the function of X-ray crystallography in the process of drug discovery and development was obtained. The purpose of this material was to offer an overview of the present status of the field and to emphasize the significant contributions that X-ray crystallography has made in the process of drug discovery. This information was categorized and synthesized.

The review also talks about the difficulties and restrictions that are involved with the use of X-ray crystallography in the process of drug discovery and development. Additionally, it covers probable future possibilities for study in this field as well as future views. In general, the purpose of this study is to provide a complete overview of the significance of X-ray crystallography in the process of drug discovery and development, as well as its potential influence on the creation of novel therapeutic agents.

4. Results and Discussion

4.1 Basics of X-ray crystallography

According to Maveyraud (2020), the discipline of X-ray crystallography has been crucial in the process of drug discovery and development. This is because it has been able to provide comprehensive three-dimensional structures of target proteins and therapeutic compounds. This part will cover the fundamentals of X-ray diffraction as well as the methods that are used in X-ray crystallography. It will emphasize the significance of these approaches in comprehending the molecular structures of biological macromolecules and the interactions that they have with smaller molecules.

4.1.1 Principles of X-ray diffraction

When X-rays interact with the crystalline structure of a sample, a phenomenon known as X-ray diffraction takes place. This phenomenon is the foundation upon which X-ray crystallography is built. According to Helliwell (2017), the electron density of the atoms in the crystal lattice causes X-rays to be diffracted when they are directed at a crystal with a known wavelength. Ascertaining the three-dimensional arrangement of atoms in a crystal may be accomplished via the use of the diffraction pattern that is detected on a detector.

The intensity and angle of diffracted X-rays provide information about the distances between atoms and the angles between chemical bonds in the crystal structure (Ferrer, 2013). By analyzing the diffraction pattern, researchers can determine the crystallographic phases and calculate electron density maps, which are used to build atomic models of the molecule being studied.

X-ray diffraction data can be collected from single crystals or from powder samples, with single crystal data typically providing higher resolution structures (Ennifar, 2013). The quality of X-ray diffraction data is crucial for determining accurate atomic positions and refining the crystal structure.

4.1.2 Techniques used in X-ray crystallography

Protein crystallography: Protein crystallography includes crystallizing target proteins and then exposing the crystals to X-ray diffraction analysis (Carvalho, 2010). Purification of the protein, crystallization, data collecting, identification of the structure, and refinement are all components of the procedure mentioned above.

High-throughput methods such as robotic crystallization systems have accelerated the protein crystallography workflow, allowing researchers to screen a large number of crystallization conditions (Blundell, 2020). Synchrotron radiation sources with high-intensity X-rays have also improved data collection speed and quality.

Small molecule crystallography: Small molecule crystallography is used to determine the structures of organic and inorganic compounds (Aitipamula, 2017). This technique is essential for drug discovery and development as it provides detailed information on the arrangement of atoms in drug molecules and their interactions with target proteins.

Cocrystallization of drug molecules with target proteins can reveal the binding mode and interactions of the drug with the target, aiding in structure-based drug design (Brader, 2017). Knowledge of the crystal structure of drug-target complexes can also help in optimizing drug potency and selectivity.

Electron density maps and model building: After solving the phase problem, electron density maps are calculated from the X-ray diffraction data to visualize the positions of atoms in the crystal lattice (Carvalho, 2010). Model building involves fitting atomic models into the electron density maps using computer software.

The refinement process involves adjusting the atomic positions and thermal parameters to improve the agreement between the observed and calculated structure factors (Erlanson, 2012). Validation tools are used to assess the quality of the refined model and identify any potential errors or artifacts.

High-resolution X-ray crystallography: Advances in X-ray sources, detectors, and data processing software have enabled high-resolution X-ray crystallography, allowing researchers to determine atomic structures at near-atomic resolution (Helliwell, 2017). High-resolution structures provide detailed insight into the geometry of chemical bonds, hydrogen bonding patterns, and conformational flexibility of molecules.

High-resolution X-ray crystallography has been instrumental in understanding the mechanisms of enzyme catalysis, drug binding, and protein-ligand interactions (Mishin, 2019). These detailed structural insights can be used to design more potent and selective drug compounds with improved pharmacological properties.

4.2 Applications of X-ray crystallography in drug discovery

4.2.1 Structural determination of drug targets

When it comes to understanding the three-dimensional structures of protein targets that are important for drug development, X-ray crystallography is essential (Rodríguez, 2020). X-ray crystallography provides high-resolution crystal structures of target proteins, which provide a thorough comprehension of the protein's binding pockets and active site. For instance, the creation of anti-HIV medications like ritonavir was made possible by the crystal structure of the HIV protease enzyme, which revealed important information about the binding interactions between the enzyme and inhibitors (Spiliopoulou, 2020). Comparably, the kinase domain structure of BCR-ABL has been useful in the development of certain inhibitors for the management of chronic myeloid leukemia.

4.2.2 Protein-ligand complex structures

X-ray crystallography is invaluable in elucidating the structures of protein-ligand complexes, providing detailed information on the binding interactions between a drug candidate and its target protein. This information can be used to optimize the binding affinity and selectivity of a drug molecule (Zhu, 2020). For instance, the crystal structure of the complex between the anti-cancer drug imatinib and the tyrosine kinase ABL revealed key hydrogen bonding interactions critical for its activity. Such insights are essential for rational drug design and optimization.

4.2.3 Fragment-based drug design

When designing drugs using the fragment-based approach, which screens tiny compounds (fragments) for the capacity to bind to a target protein, X-ray crystallography is a commonly used technique. Researchers may find important interactions that influence binding affinity and direct the creation of more effective lead compounds by figuring out the crystal structures of fragment-protein complexes (Sinha, 2018). For instance, the creation of new inhibitors for kinases and other protein targets has resulted from the use of X-ray crystallography in fragment-based drug design. The creation of bigger ligands with better potency and selectivity might begin with the crystal structure of a fragment attached to its target protein (Mastrangelo, 2013).

4.2.4 Structure-based drug design

Structure-based drug design uses information on the three-dimensional structure of a target protein to create compounds that precisely interact with a protein's active site. This strategy heavily relies on X-ray crystallography, which offers comprehensive details on the ligand binding mechanism within the protein pocket (Hennig, 2011). For instance, the crystal structure of the influenza neuraminidase enzyme complexed with the drug oseltamivir (Tamiflu) revealed the precise interactions between the drug and the enzyme, guiding the design of more potent analogs (Ferrer, 2013). By leveraging structural information obtained through X-ray crystallography, researchers can optimize drug candidates for improved efficacy, reduce off-target effects, and enhance drug selectivity.

4.3 Case studies

4.3.1 Examples of successful drug discovery programs using X-ray crystallography

X-ray crystallography has revolutionized drug discovery and development by providing detailed structural information about drug-target interactions (Davies, 2012). Several successful drug discovery programs have utilized X-ray crystallography to design novel drugs with improved efficacy and specificity. One such example is the development of the drug Tamiflu (oseltamivir) for the treatment of influenza (Blundell, 2020). The crystal structure of the viral neuraminidase enzyme complexed with oseltamivir provided key insights into the binding mode of the drug and guided the optimization of its chemical structure to enhance its potency against influenza viruses.

The development of HIV protease inhibitors, including lopinavir and ritonavir, is another noteworthy example. More effective and targeted medications for the treatment of HIV/AIDS have been developed as a result of X-ray crystallography investigations of the HIV protease enzyme in combination with these inhibitors, which provided insight into the molecular mechanisms behind their binding interactions (Ennifar, 2013). Furthermore, X-ray crystallography has proved useful in the development of antibiotics that target the ribosomes of bacteria. The logical design of novel antibiotics with enhanced antibacterial activity and a wider range of action has been aided by the crystal structures of ribosomal subunits attached to drugs such as tetracycline and linezolid (García-Nafría, 2020).

4.3.2 Impact of X-ray crystallography on drug development

Because it has provided vital structural insights into the interactions between therapeutic compounds and their target proteins, X-ray crystallography has had a revolutionary effect on drug development (Maveyraud, 2020). Researchers are able to create safer, more effective medications that are also more powerful because of this comprehensive structural knowledge. X-ray crystallography helps to rationally design new drugs with improved pharmacological properties by elucidating the three-dimensional structure of drug-target complexes at atomic resolution. This process allows for the identification of important binding sites, optimal drug conformations, and potential off-target interactions (Mazzorana, 2020).

Furthermore, throughout the medication development process, X-ray crystallography is essential for optimizing lead molecules (Shi, 2014). Researchers may find structural alterations that improve a drug's binding affinity, specificity, and pharmacokinetic characteristics by analyzing the crystal structures of lead compounds attached to their target proteins (Zheng, 2015). This rational design approach minimizes the need for costly and time-consuming trial-and-error experiments, accelerating the drug discovery process and increasing the success rate of drug development programs.

Furthermore, X-ray crystallography has facilitated the study of drug resistance mechanisms by revealing structural changes in target proteins that confer resistance to drugs (Aitipamula, 2017). This knowledge is essential for designing new drugs that can overcome resistance mutations and maintain their efficacy against drug-resistant strains of pathogens.

4.4 Challenges and limitations

X-ray crystallography plays a critical role in drug discovery and development by providing detailed structural information on target proteins or enzymes, which is essential for understanding their function and designing novel therapeutics (Cooper, 2011). However, this technique is not without its challenges and limitations, which can impact the quality and reliability of the structural data obtained. In this section, we will discuss some of the major issues in crystallization, resolution and accuracy limitations, as well as methods to overcome these challenges (Brader, 2017).

4.4.1 Issues in Crystallization

One of the primary challenges in X-ray crystallography is obtaining high-quality protein crystals suitable for data collection. Protein crystallization is a complex and highly variable process, and not all proteins readily crystallize under standard conditions (Carvalho, 2010). Factors such as protein purity, stability, concentration, pH, temperature, and additives can all influence the crystallization outcome (Erlanson, 2012). In some cases, proteins may require extensive optimization of crystallization conditions, including the use of different precipitants, buffers, or screening methods to obtain well-ordered crystals.

For example, researchers studying the structure of a membrane protein may encounter difficulties in obtaining diffraction-quality crystals due to the hydrophobic nature of these proteins and their tendency to aggregate or form non-native oligomers (Helliwell, 2017). In such cases, innovative strategies such as the use of lipid cubic phase or bicelle crystallization techniques may be employed to stabilize the protein in a native-like environment and promote crystal growth.

4.4.2 Resolution and Accuracy Limitations

Another limitation of X-ray crystallography is the resolution and accuracy of the obtained structures. The resolution of a crystal structure refers to the level of detail that can be observed in the electron density map, with higher resolution data providing more accurate and interpretable structural information (Mishin, 2019). However, achieving high resolution data can be challenging, especially for large complexes or flexible proteins that may exhibit conformational heterogeneity.

Furthermore, the quality of the crystal diffraction data can be influenced by factors such as radiation damage, twinning, anisotropy, and crystal packing effects. These factors can limit the accuracy of the final model and lead to errors in the interpretation of the structure (Rodríguez, 2020). In some cases, researchers may need to collect multiple datasets at different radiation doses or use advanced data processing techniques to improve the resolution and reliability of the structural results.

4.4.3 Methods to overcome challenges

To address the challenges and limitations of X-ray crystallography in drug discovery and development, researchers have developed a variety of strategies and techniques to improve the success rate and quality of crystal structures. Some of these methods include:

High-through screening platforms are used to efficiently identify crystallization conditions. Automated liquid handling systems and robotic platforms can accelerate the process of screening hundreds or thousands of crystallization conditions, increasing the likelihood of obtaining high-quality crystals (Spiliopoulou, 2020).

Co-crystallization with ligands or inhibitors: Co-crystallizing the protein of interest with small molecules or ligands can help improve the stability and crystallization propensity of the protein. Moreover, these co-crystals can provide valuable information on the binding mode and interactions between the protein and ligand, facilitating structure-based drug design (Zhu, 2020).

Advanced data collection and processing techniques: Employing state-of-the-art synchrotron beamlines and data collection strategies, such as serial crystallography or microfocus beamlines, can enhance the quality and resolution of crystal diffraction data. Additionally, advanced data processing software and algorithms, such as Bayesian methods or maximum likelihood estimation, can help overcome resolution limitations and improve the accuracy of the final structural models (Mastrangelo, 2013).

4.5 Future perspectives

4.5.1 Advances in X-ray crystallography for drug discovery

X-ray crystallography has made significant advances in guiding drug discovery and development processes (Ferrer, 203). One key advancement is the development of synchrotron radiation sources, which have significantly enhanced data collection capabilities by providing intense and tunable X-ray beams (Hennig, 2011). This has enabled researchers to collect high-quality diffraction data from smaller and more challenging crystals, leading to improved structure determination and accuracy of ligand binding interactions.

Additionally, advancements in X-ray detectors, such as CCDs and pixel array detectors, have led to increased data acquisition speed and improved signal-to-noise ratios (Davies, 2012). These developments have not only accelerated structure determination but also enabled the

study of dynamic protein-ligand interactions, providing valuable insights for drug design and optimization.

Furthermore, computational methods, including molecular dynamics simulations and fragment-based approaches, have been integrated with X-ray crystallography to enhance the speed and accuracy of drug discovery (Blundell, 2020). These computational approaches help in predicting ligand binding modes and interactions before experimental structure determination, allowing for efficient screening of large chemical libraries.

4.5.2 Integration with other techniques for a comprehensive understanding

While X-ray crystallography provides detailed structural information on protein-ligand complexes, it is often limited to static snapshots of molecules in crystalline form (Aitipamula, 2017). To overcome this limitation and gain a comprehensive understanding of drug-target interactions, X-ray crystallography is often integrated with other techniques such as NMR spectroscopy, mass spectrometry, and cryo-electron microscopy.

NMR spectroscopy, for example, can give valuable information on protein dynamics and conformational changes in solution, complementing the static structural data obtained from X-ray crystallography (Ennifar, 2013). By combining both techniques, researchers can gain insights into the flexibility and binding kinetics of protein-ligand complexes, which is crucial for rational drug design.

Mass spectrometry-based techniques, such as HDX and native mass spectrometry, can further elucidate protein dynamics, stability, and oligomeric states, providing additional information on drug binding mechanisms and allosteric regulation (Cooper, 2011). Integrating these techniques with X-ray crystallography allows for a more comprehensive characterization of the structure-function relationships of drug targets.

Cryo-EM microscopy has also emerged as a powerful tool for studying protein complexes at near-atomic resolution, particularly for large macromolecular assemblies and membrane proteins that are challenging to crystallize (García-Nafría, 2020). By combining cryo-EM with X-ray crystallography, researchers can obtain complementary structural information on protein-ligand complexes in different conformations and states, allowing for a more complete understanding of drug-target interactions.

5. Conclusion

In summary, X-ray crystallography has become an invaluable resource for understanding the structure and function of target proteins, making it a potent tool in the drug discovery and development process. The use of X-ray crystallography facilitates the rational creation of new medications with enhanced safety and effectiveness profiles by unveiling the atomic features of protein-ligand interactions. Additionally, improvements in computational techniques and apparatus have made X-ray crystallography more effective and accessible, opening the door for the quick discovery of novel therapeutic possibilities. X-ray crystallography is expected to have a significant impact on how drugs are discovered and developed in the future as the discipline develops.

References

Aitipamula, S., & Vangala, V. R. (2017). X-ray crystallography and its role in understanding the physicochemical properties of pharmaceutical cocrystals. Journal of the Indian Institute of Science, 97, 227-243.

Brader, M. L., Baker, E. N., Dunn, M. F., Laue, T. M., & Carpenter, J. F. (2017). Using X-ray crystallography to simplify and accelerate biologics drug development. Journal of Pharmaceutical Sciences, 106(2), 477-494.

Blundell, T. L. (2020). A personal history of using crystals and crystallography to understand biology and advanced drug discovery. Crystals, 10(8), 676.

Cooper, D. R., Porebski, P. J., Chruszcz, M., & Minor, W. (2011). X-ray crystallography: assessment and validation of protein–small molecule complexes for drug discovery. Expert opinion on drug discovery, 6(8), 771-782.

Carvalho, A. L., Trincão, J., & Romão, M. J. (2010). X-ray crystallography in drug discovery. Ligand-macromolecular interactions in drug discovery: methods and protocols, 31-56.

Davies, T. G., & Tickle, I. J. (2012). Fragment screening using X-ray crystallography. Fragment-Based Drug Discovery and X-Ray Crystallography, 33-59.

Ennifar, E. (2013). X-ray crystallography as a tool for mechanism-of-action studies and drug discovery. Current pharmaceutical biotechnology, 14(5), 537-550.

Erlanson, D. A. (2012). Introduction to fragment-based drug discovery. Fragment-based drug discovery and X-ray crystallography, 1-32.

Ferrer, J. L., Larive, N. A., Bowler, M. W., & Nurizzo, D. (2013). Recent progress in robot-based systems for crystallography and their contribution to drug discovery. Expert opinion on drug discovery, 8(7), 835-847.

García-Nafría, J., & Tate, C. G. (2020). Cryo-electron microscopy: moving beyond X-ray crystal structures for drug receptors and drug development. Annual review of pharmacology and toxicology, 60, 51-71.

Helliwell, J. R. (2017). New developments in crystallography: exploring its technology, methods and scope in the molecular biosciences. Bioscience reports, 37(4), BSR20170204.

Hennig, M., Ruf, A., & Huber, W. (2011). Combining biophysical screening and X-ray crystallography for fragment-based drug discovery. Fragment-Based Drug Discovery and X-Ray Crystallography, 115-143.

Maveyraud, L., & Mourey, L. (2020). Protein X-ray crystallography and drug discovery. Molecules, 25(5), 1030.

Mishin, A., Gusach, A., Luginina, A., Marin, E., Borshchevskiy, V., & Cherezov, V. (2019). An outlook on using serial femtosecond crystallography in drug discovery. Expert Opinion on Drug Discovery, 14(9), 933-945.

Mastrangelo, E., Nardini, M., & Bolognesi, M. (2013). One hundred years of X-ray diffraction, 50 years of structural biology. Rendiconti Lincei, 24, 93-99.

Mazzorana, M., Shotton, E. J., & Hall, D. R. (2020). A comprehensive approach to X-ray crystallography for drug discovery at a synchrotron facility—The example of Diamond Light Source. Drug Discovery Today: Technologies, 37, 83-92.

Rodríguez, I., Gautam, R., & Tinoco, A. D. (2020). Using x-ray diffraction techniques for biomimetic drug development, formulation, and polymorphic characterization. Biomimetics, 6(1), 1.

Sinha, S., & Vohora, D. (2018). Drug discovery and development: An overview. Pharmaceutical medicine and translational clinical research, 19-32.

Shi, Y. (2014). A glimpse of structural biology through X-ray crystallography. Cell, 159(5), 995-1014.

Spiliopoulou, M., Valmas, A., Triandafillidis, D. P., Kosinas, C., Fitch, A., Karavassili, F., & Margiolaki, I. (2020). Applications of X-ray powder diffraction in protein crystallography and drug screening. Crystals, 10(2), 54.

Zheng, H., Handing, K. B., Zimmerman, M. D., Shabalin, I. G., Almo, S. C., & Minor, W. (2015). X-ray crystallography over the past decade for novel drug discovery–where are we heading next? Expert opinion on drug discovery, 10(9), 975-989.

Zhu, L., Chen, X., Abola, E. E., Jing, L., & Liu, W. (2020). Serial crystallography for structure-based drug discovery. Trends in pharmacological sciences, 41(11), 830-839.